ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)

ImmuneOncia Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	28,495	8,226	20,957	26,730	36,320	12,027
Short-Term Investments	10,100	3,100	5,000	-	6,000	8,708
Cash & Short-Term Investments	38,595	11,326	25,957	26,730	42,320	20,735
Cash Growth	44.39%	-56.36%	-2.89%	-36.84%	104.10%	-23.41%
Accounts Receivable	65.39	421.83	11	633.65	-	-
Other Receivables	1,446	7,709	172.13	202.16	41.53	49.3
Receivables	1,512	8,131	183.13	835.81	41.53	49.3
Prepaid Expenses	5,419	297.34	376.95	520.18	232.62	98.18
Other Current Assets	121.19	107.93	118.97	884.02	72.89	38.05
Total Current Assets	45,647	19,863	26,636	28,970	42,667	20,920
Property, Plant & Equipment	386.81	494.54	892.1	547.33	997.96	835.55
Other Intangible Assets	4,623	4,908	5,429	5,987	6,503	7,064
Other Long-Term Assets	1,249	930.02	838.32	188.36	932.89	175.63
Total Assets	51,906	26,195	33,795	35,693	51,101	28,996
Accrued Expenses	137.63	137.63	103.34	154.4	128.24	214.87
Current Portion of Leases	49.25	51.05	50.11	98.69	216.39	76.78
Current Unearned Revenue	1,950	1,950	1,950	1,950	6,902	18.62
Other Current Liabilities	1,892	4,354	1,268	1,646	1,578	1,262
Total Current Liabilities	4,029	6,493	3,372	3,850	8,824	1,572
Long-Term Leases	20.23	44.01	86.83	24.27	98.24	24.47
Other Long-Term Liabilities	279.74	219.18	236.63	84,226	101,526	52,929
Total Liabilities	4,400	6,771	3,710	88,100	110,633	54,526
Common Stock	36,953	36,365	26,896	26,141	25,503	23,128
Additional Paid-In Capital	114,758	79,021	35,292	28,046	22,148	-
Retained Earnings	-118,346	-110,721	-105,016	-113,921	-110,518	-50,045
Comprehensive Income & Other	14,140	14,759	8,637	7,326	3,336	1,387
Total Common Equity	47,505	19,424	-34,192	-52,407	-59,532	-25,530
Shareholders' Equity	47,505	19,424	30,086	-52,407	-59,532	-25,530
Total Liabilities & Equity	51,906	26,195	33,795	35,693	51,101	28,996
Total Debt	69.48	95.06	136.94	122.97	314.63	101.26
Net Cash (Debt)	38,525	11,231	25,820	26,607	42,005	20,633
Net Cash Growth	44.80%	-56.50%	-2.96%	-36.66%	103.58%	-23.17%
Net Cash Per Share	615.84	199.46	492.28	510.53	904.13	4461.02
Filing Date Shares Outstanding	73.91	56.31	52.45	52.12	46.46	4.63
Total Common Shares Outstanding	73.91	56.31	52.45	52.12	46.46	4.63
Working Capital	41,617	13,370	23,264	25,120	33,842	19,348
Book Value Per Share	642.78	344.97	-651.90	-1005.59	-1281.39	-5519.70
Tangible Book Value	42,883	14,516	-39,621	-58,394	-66,035	-32,594
Tangible Book Value Per Share	580.23	257.81	-755.41	-1120.48	-1421.36	-7047.03
Machinery	1,538	1,514	1,443	1,173	1,148	1,053

Source: S&P Global Market Intelligence. Standard template. Financial Sources.